Zdzislaw Szulc to Enzyme Inhibitors
This is a "connection" page, showing publications Zdzislaw Szulc has written about Enzyme Inhibitors.
Connection Strength
0.966
-
Mechanistic insights into ceramidase inhibitor LCL521-enhanced tumor cell killing by photodynamic and thermal ablation therapies. Photochem Photobiol Sci. 2020 Sep 09; 19(9):1145-1151.
Score: 0.555
-
Interaction of acid ceramidase inhibitor LCL521 with tumor response to photodynamic therapy and photodynamic therapy-generated vaccine. Int J Cancer. 2016 09 15; 139(6):1372-8.
Score: 0.103
-
Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs. Bioorg Med Chem. 2014 Dec 15; 22(24):6933-44.
Score: 0.092
-
Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats. Behav Brain Res. 2009 Jan 30; 197(1):41-4.
Score: 0.060
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.058
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.055
-
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
Score: 0.028
-
Synthesis and bioevaluation of omega-N-amino analogs of B13. Bioorg Med Chem. 2009 Mar 01; 17(5):1840-8.
Score: 0.016